| Íàèìåíîâàíèå | Ïðîèçâîäèòåëü | Öåíà $ | Öåíà ðóá
|
|---|
| ÔÀËÈÌÈÍÒ ÄÐÀÆÅ 25ÌÃ ¹20 (BERLIN-CHEMIE, ÃÅÐÌÀÍÈß) | BERLIN-CHEMIE | | 93.33
|
| ÔÀÌÎÒÈÄÈÍ ÒÀÁ. 20ÌÃ ¹20 (ÁÈÎÊÎÌ ÇÀÎ, ÐÎÑÑÈß) | ÁÈÎÊÎÌ ÇÀÎ | | 8.89
|
| ÔÀÌÎÒÈÄÈÍ ÒÀÁ. Ï/Î 20ÌÃ ¹30 (ÎÇÎÍ, ÐÎÑÑÈß) | ÎÇÎÍ | | 13.15
|
| ÔÀÌÎÒÈÄÈÍ ÒÀÁ. Ï/Î 40ÌÃ ¹10 (ÎÇÎÍ, ÐÎÑÑÈß) | ÎÇÎÍ | | 8.56
|
| ÔÀÌÎÒÈÄÈÍ ÒÀÁ. Ï/Î 40ÌÃ ¹20 (ÁÈÎÊÎÌ ÇÀÎ, ÐÎÑÑÈß) | ÁÈÎÊÎÌ ÇÀÎ | | 15.83
|
| ÔÀÐÈÍÃÎÑÅÏÒ ÒÀÁ. 10ÌÃ ¹10 (TERAPIA S.A., ÐÓÌÛÍÈß) | TERAPIA S.A. | | 40.02
|
| ÔÀÐÈÍÃÎÑÅÏÒ ÒÀÁ. 10ÌÃ ¹10 (ËÈÌÎÍ) (TERAPIA S.A., ÐÓÌÛÍÈß) | TERAPIA S.A. | | 38.85
|
| ÔÀÐÈÍÃÎÑÅÏÒ ÒÀÁ. 10ÌÃ ¹20 (TERAPIA S.A., ÐÓÌÛÍÈß) | TERAPIA S.A. | | 58.94
|
| ÔÀÐÈÍÃÎÑÅÏÒ ÒÀÁ. 10ÌÃ ¹20 (ËÈÌÎÍ) (TERAPIA S.A., ÐÓÌÛÍÈß) | TERAPIA S.A. | | 61.71
|
| ÔÀÐÌÀÒÅÊÑ ÊÐÅÌ ÂÀÃÈÍÀËÜÍÛÉ 72Ã ¹1 (INNOTECH INTERNATIONAL, ÔÐÀÍÖÈß) | INNOTECH INTERNATIONAL | | 192.51
|
| ÔÀÐÌÀÒÅÊÑ ÑÓÏÏ. ÂÀÃÈÍÀËÜÍÛÅ ¹10 (INNOTECH INTERNATIONAL, ÔÐÀÍÖÈß) | INNOTECH INTERNATIONAL | | 245.12
|
| ÔÀÐÌÀÒÅÊÑ ÒÀÁ. ÂÀÃ. 20ÌÃ ¹12 (INNOTECH INTERNATIONAL, ÔÐÀÍÖÈß) | INNOTECH INTERNATIONAL | | 170.23
|
| ÔÀÑÒÓÌ ÃÅËÜ 2,5% 30Ã ¹1 (BERLIN-CHEMIE/MENARINI, ÈÒÀËÈß) | BERLIN-CHEMIE/MENARINI | | 169.45
|
| ÔÀÑÒÓÌ ÃÅËÜ 2,5% 50Ã ¹1 (BERLIN-CHEMIE/MENARINI, ÈÒÀËÈß) | BERLIN-CHEMIE/MENARINI | | 208.25
|
| ÔÅÁÐÎÔÈÄ ÃÅËÜ 2,5% 30Ã ¹1 (MEDANA PHARMA TERPOL, ÏÎËÜØÀ) | MEDANA PHARMA TERPOL | | 130.36
|
| ÔÅÁÐÎÔÈÄ ÃÅËÜ 2,5% 50Ã ¹1 (MEDANA PHARMA TERPOL, ÏÎËÜØÀ) | MEDANA PHARMA TERPOL | | 173.7
|
| ÔÅÂÀÐÈÍ ÒÀÁ. Ï/Î 50ÌÃ ¹15 (SOLVAY PHARMACEUTICALS, ÔÐÀÍÖÈß) | SOLVAY PHARMACEUTICALS | | 545.38
|
| ÔÅÇÀÌ ÊÀÏÑ. ¹60 (BALKANPHARMA, ÁÎËÃÀÐÈß) | BALKANPHARMA | | 130.69
|
| ÔÅÊÑÀÄÈÍ ÒÀÁ. Ï/Î 120ÌÃ ¹10 (RANBAXY, ÈÍÄÈß) | RANBAXY | | 118.47
|
| ÔÅÊÑÀÄÈÍ ÒÀÁ. Ï/Î 180ÌÃ ¹10 (RANBAXY, ÈÍÄÈß) | RANBAXY | | 185.49
|
| ÔÅËÎÄÈÏ ÐÅÒÀÐÄ ÒÀÁ. 10Ìà ¹30 (IVAX PHARMACEUTICALS, ×ÅÕÈß) | IVAX PHARMACEUTICALS | | 515.65
|
| ÔÅËÎÄÈÏ ÐÅÒÀÐÄ ÒÀÁ. Ï/Î 5Ìà ¹30 (IVAX PHARMACEUTICALS, ×ÅÕÈß) | IVAX PHARMACEUTICALS | | 331.67
|
| ÔÅÌÈÍÀËÜÃÈÍ ÒÀÁ. ÃÎÌÅÎÏ. ¹20 (ÌÀÒÅÐÈÀ ÌÅÄÈÊÀ ÕÎËÄÈÍÃ, ÐÎÑÑÈß) | ÌÀÒÅÐÈÀ ÌÅÄÈÊÀ ÕÎËÄÈÍÃ | | 26.52
|
| ÔÅÌÎÄÅÍ ÄÐÀÆÅ ¹21 (SCHERING A.G, ÃÅÐÌÀÍÈß) | SCHERING A.G | | 439.84
|
| ÔÅÍÀÇÅÏÀÌ (ÝËÇÅÏÀÌ) Ð-Ð ÄËß Â/Â È Â/Ì ÂÂÅÄ. 0,1% 1ÌË ¹10 (ÝËËÀÐÀ, ÐÎÑÑÈß) | ÝËËÀÐÀ | | 103.1
|
| ÔÅÍÀÇÅÏÀÌ Ð-Ð ÄËß Â/Â È Â/Ì ÂÂÅÄ. 0,1% 1ÌË ¹10 (ÍÎÂÎÑÈÁÕÈÌÔÀÐÌ, ÐÎÑÑÈß) | ÍÎÂÎÑÈÁÕÈÌÔÀÐÌ | | 116.82
|
| ÔÅÍÀÇÅÏÀÌ ÒÀÁ. 0,5ÌÃ ¹50 (ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ, ÐÎÑÑÈß) | ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ | | 59.73
|
| ÔÅÍÀÇÅÏÀÌ ÒÀÁ. 1ÌÃ ¹50 (ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ, ÐÎÑÑÈß) | ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ | | 75.89
|
| ÔÅÍÀÇÅÏÀÌ ÒÀÁ. 2,5ÌÃ ¹50 (ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ, ÐÎÑÑÈß) | ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ | | 118.23
|
| ÔÅÍÈÁÓÒ ÒÀÁ. 250ÌÃ ¹20 (ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ, ÁÅËÀÐÓÑÜ) | ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ | | 75.79
|
| ÔÅÍÈÁÓÒ ÒÀÁ. 250ÌÃ ¹20 (ÎÇÎÍ, ÐÎÑÑÈß) | ÎÇÎÍ | | 75.45
|
| ÔÅÍÈÃÈÄÈÍ ÒÀÁ. 10ÌÃ ¹50 (ËÓÃÀÍÑÊÈÉ ÕÔÇ, ÓÊÐÀÈÍÀ) | ËÓÃÀÍÑÊÈÉ ÕÔÇ | | 6.59
|
| ÔÅÍÈËÈÍ ÒÀÁ. 30ÌÃ ¹20 (ÇÄÎÐÎÂÜÅ ÔÊ, ÓÊÐÀÈÍÀ) | ÇÄÎÐÎÂÜÅ ÔÊ | | 51.78
|
| ÔÅÍÈÑÒÈË ÃÅËÜ 0,1% 30Ã ¹1 (NOVARTIS CONSUMER HEALTH, ØÂÅÉÖÀÐÈß) | NOVARTIS CONSUMER HEALTH | | 196.81
|
| ÔÅÍÈÑÒÈË ÃÅËÜ Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 0,1% 50Ã N1 (NOVARTIS CONSUMER HEALTH, ØÂÅÉÖÀÐÈß) | NOVARTIS CONSUMER HEALTH | | 211.72
|
| ÔÅÍÈÑÒÈË ÊÀÏËÈ 0,1% 20ÌË ¹1 (NOVARTIS CONSUMER HEALTH, ØÂÅÉÖÀÐÈß) | NOVARTIS CONSUMER HEALTH | | 213.52
|
| ÔÅÍÈÑÒÈË ÏÅÍÖÈÂÈÐ ÊÐÅÌ 1% 2Ã ¹1 (NOVARTIS CONSUMER HEALTH, ÃÅÐÌÀÍÈß) | NOVARTIS CONSUMER HEALTH | | 207.24
|
| ÔÅÍÊÀÐÎË ÒÀÁ. 10ÌÃ ¹20 (ÎËÀÉÍÔÀÐÌ, ËÀÒÂÈß) | ÎËÀÉÍÔÀÐÌ | | 102.17
|
| ÔÅÍÊÀÐÎË ÒÀÁ. 25ÌÃ ¹20 (ÎËÀÉÍÔÀÐÌ, ËÀÒÂÈß) | ÎËÀÉÍÔÀÐÌ | | 146.97
|
| ÔÅÍÎÁÀÐÁÈÒÀË ÒÀÁ. 100ÌÃ ¹10 (ÀÑÔÀÐÌÀ ÎÎÎ, ÐÎÑÑÈß) | ÀÑÔÀÐÌÀ ÎÎÎ | | 7.36
|
| ÔÅÍÎÊÑÈÌÅÒÈËÏÅÍÈÖÈËËÈÍ ÒÀÁ. 250ÌÃ ¹10 (ÑÈÍÒÅÇ ÀÊÎÌÏ, ÐÎÑÑÈß) | ÑÈÍÒÅÇ ÀÊÎÌÏ | | 13.29
|
| ÔÅÍÎÒÐÎÏÈË ÒÀÁ. 100ÌÃ ¹10 (ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ, ÐÎÑÑÈß) | ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ | | 311.45
|
| ÔÅÍÎÒÐÎÏÈË ÒÀÁ. 100ÌÃ ¹30 (ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ, ÐÎÑÑÈß) | ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ | | 754.07
|
| ÔÅÍÕÅËß ÏËÎÄÛ 50à ¹1 (ÈÂÀÍ-×ÀÉ ÇÀÎ, ÐÎÑÑÈß) | ÈÂÀÍ-×ÀÉ ÇÀÎ | | 16.87
|
| ÔÅÍÞËÜÑ ÊÀÏÑ. ¹10 (RANBAXY, ÈÍÄÈß) | RANBAXY | | 41.83
|
| ÔÅÍÞËÜÑ ÊÀÏÑ. ¹30 (RANBAXY, ÈÍÄÈß) | RANBAXY | | 80.73
|
| ÔÅÐÂÅÊÑ ÄËß ÄÅÒÅÉ ÏÎÐÎØÎÊ ¹8 (BRISTOL MYERS SQUIBB, ÑØÀ) | BRISTOL MYERS SQUIBB | | 128.61
|
| ÔÅÐÂÅÊÑ ÏÎÐ.Á/ÑÀÕ. ¹8 (ËÈÌÎÍ) (BRISTOL MYERS SQUIBB, ÔÐÀÍÖÈß) | BRISTOL MYERS SQUIBB | | 137.08
|
| ÔÅÐÂÅÊÑ ÏÎÐ.Ñ ÑÀÕ. ¹8 (ËÈÌÎÍ) (BRISTOL MYERS SQUIBB, ÔÐÀÍÖÈß) | BRISTOL MYERS SQUIBB | | 137.03
|
| ÔÅÐÂÅÊÑ ÏÎÐÎØÎÊ ¹8 (ÌÀËÈÍÀ) (BRISTOL MYERS SQUIBB, ÔÐÀÍÖÈß) | BRISTOL MYERS SQUIBB | | 137.75
|
| ÔÅÐËÀÒÓÌ Ð-Ð Ä/ÂÍÓÒÐ.ÏÐÈÌ. 800ÌÃ/15ÌË ¹10 (ITALFARMACO, ÈÒÀËÈß) | ITALFARMACO | | 438.69
|
| ÔÅÐÎÃËÎÁÈÍ Â-12 ÑÈÐÎÏ 200ÌË ¹1 (VITABIOTICS LTD, ÃÅÐÌÀÍÈß) | VITABIOTICS LTD | | 257.25
|
| ÔÅÐÐÅÒÀÁ ÊÎÌÏ ÊÀÏÑ. ÏÐÎËÎÍÃ.ÄÅÉÑÒÂ. ¹30 (LANNACHER HEILMITTEL GMBH, ÀÂÑÒÐÈß) | LANNACHER HEILMITTEL GMBH | | 67.95
|
| ÔÅÐÐÎ-ÔÎËÜÃÀÌÌÀ ÊÀÏÑ. ¹20 (WOERWAG PHARMA GMBH, ÃÅÐÌÀÍÈß) | WOERWAG PHARMA GMBH | | 107.82
|
| ÔÅÐÐÎ-ÔÎËÜÃÀÌÌÀ ÊÀÏÑ. ¹20 (Ñ.Ï.Ì. ÊÎÍÒÐÀÊÒ ÔÀÐÌÀ ÃÌÁÕ È ÊÎ ÊÃ, ÃÅÐÌÀÍÈß) | Ñ.Ï.Ì. ÊÎÍÒÐÀÊÒ ÔÀÐÌÀ ÃÌÁÕ È ÊÎ ÊÃ | | 107.3
|
| ÔÅÐÐÓÌ ËÅÊ Ð-Ð ÄËß Â/Ì ÂÂÅÄ. 2ÌË ¹5 (LEK, ÑËÎÂÅÍÈß) | LEK | | 436.15
|
| ÔÅÐÐÓÌ ËÅÊ Ð-Ð ÄËß Â/Ì ÂÂÅÄ. 2ÌË ¹50 (LEK, ÑËÎÂÅÍÈß) | LEK | | 4225.32
|
| ÔÅÐÐÓÌ ËÅÊ ÑÈÐÎÏ 50ÌÃ / 5ÌË 100ÌË ¹1 (LEK, ÑËÎÂÅÍÈß) | LEK | | 135.72
|
| ÔÅÐÐÓÌ ËÅÊ ÒÀÁ. ÆÅÂÀÒ. 100ÌÃ ¹30 (LEK, ÑËÎÂÅÍÈß) | LEK | | 272.33
|
| ÔÅÑÒÀË ÄÐÀÆÅ ¹100 (AVENTIS PHARMA, ÈÍÄÈß) | AVENTIS PHARMA | | 299.7
|
| ÔÅÑÒÀË ÄÐÀÆÅ ¹20 (AVENTIS PHARMA, ÈÍÄÈß) | AVENTIS PHARMA | | 58.28
|
| ÔÈÀËÊÈ ÒÐÅÕÖÂÅÒÍÎÉ ÒÐÀÂÀ 1,5Ã ¹20 Ô/ÏÀÊ. (ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ, ÐÎÑÑÈß) | ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ | | 38.25
|
| ÔÈÀËÊÈ ÒÐÅÕÖÂÅÒÍÎÉ ÒÐÀÂÀ 50Ã ¹1 (ÇÄÎÐÎÂÜÅ, ÐÎÑÑÈß) | ÇÄÎÐÎÂÜÅ | | 29.47
|
| ÔÈÇÈÎÌÅÐ ÑÏÐÅÉ ÍÀÇ. 135ÌË ¹1 (LABORATOIRES GOEMAR S.A., ÔÐÀÍÖÈß) | LABORATOIRES GOEMAR S.A. | | 305.56
|
| ÔÈÇÈÎÌÅÐ ÑÏÐÅÉ ÍÀÇ. 210ÌË ¹1 (LABORATOIRES GOEMAR S.A., ÔÐÀÍÖÈß) | LABORATOIRES GOEMAR S.A. | | 330.33
|
| ÔÈÇÈÎÌÅÐ ÑÏÐÅÉ ÍÀÇ.Ä/Ä 115ÌË ¹1 (LABORATOIRES GOEMAR S.A., ÔÐÀÍÖÈß) | LABORATOIRES GOEMAR S.A. | | 263.61
|
| ÔÈÇÈÎÌÅÐ ÔÎÐÒÅ ÑÏÐÅÉ ÍÀÇ. 210ÌË ¹1 (LABORATOIRES GOEMAR S.A., ÔÐÀÍÖÈß) | LABORATOIRES GOEMAR S.A. | | 325.67
|
| ÔÈÇÈÎÒÅÍÇ ÒÀÁ. Ï/Î 0,2ÌÃ ¹14 (ROTTENDORF PHARMA/SOLVAY, ÔÐÀÍÖÈß) | ROTTENDORF PHARMA/SOLVAY | | 245.15
|
| ÔÈÇÈÎÒÅÍÇ ÒÀÁ. Ï/Î 0,4ÌÃ ¹14 (SOLVAY PHARMA, ÃÅÐÌÀÍÈß) | SOLVAY PHARMA | | 380.12
|
| ÔÈÊÑÀÒÎÐ ÀÍÀÒÎÌÈ×.ÏÎÄÃ.SAN SENI EX.LARGE ¹2 (TZMO SA, ÏÎËÜØÀ) | TZMO SA | | 72.16
|
| ÔÈÊÑÀÒÎÐ ÀÍÀÒÎÌÈ×.ÏÎÄÃ.SAN SENI LARGE ¹2 (TZMO SA, ÏÎËÜØÀ) | TZMO SA | | 66.27
|
| ÔÈËÜÒÐÓÌ-ÑÒÈ ÒÀÁ. 400ÌÃ ¹10 (ÑÒÈ-ÌÅÄ-ÑÎÐÁ, ÐÎÑÑÈß) | ÑÒÈ-ÌÅÄ-ÑÎÐÁ | | 52.93
|
| ÔÈËÜÒÐÓÌ-ÑÒÈ ÒÀÁ. 400ÌÃ ¹50 (ÑÒÈ-ÌÅÄ-ÑÎÐÁ, ÐÎÑÑÈß) | ÑÒÈ-ÌÅÄ-ÑÎÐÁ | | 137.4
|
| ÔÈËÜÒÐÓÌ-ÑÒÈ ÒÀÁ. 400ÌÃ ¹50 (ÑÒÈ-ÌÅÄ-ÑÎÐÁ/ÀÂÂÀ ÐÓÑ, ÐÎÑÑÈß) | ÑÒÈ-ÌÅÄ-ÑÎÐÁ/ÀÂÂÀ ÐÓÑ | | 141.88
|
| ÔÈÍÀËÃÅËÜ ÃÅËÜ 0,5% 35Ã ¹1 (BOEHRINGER INGELHEIM, ÃÅÐÌÀÍÈß) | BOEHRINGER INGELHEIM | | 188.84
|
| ÔÈÍÀËÃÎÍ ÌÀÇÜ 20Ã ¹1 (BOEHRINGER INGELHEIM, ÃÅÐÌÀÍÈß) | BOEHRINGER INGELHEIM | | 184.67
|
| ÔÈÍÀÑÒ ÒÀÁ. Ï/Î 5ÌÃ ¹30 (DR. REDDYS LAB., ÈÍÄÈß) | DR. REDDYS LAB. | | 308.67
|
| ÔÈÍËÅÏÑÈÍ ÐÅÒÀÐÄ ÒÀÁ. 200ÌÃ ¹50 (AWD, ÃÅÐÌÀÍÈß) | AWD | | 166.54
|
| ÔÈÍËÅÏÑÈÍ ÐÅÒÀÐÄ ÒÀÁ. 200ÌÃ ¹50 (PLIVA, ÏÎËÜØÀ) | PLIVA | | 165.05
|
| ÔÈÍËÅÏÑÈÍ ÒÀÁ. 200ÌÃ ¹50 (AWD, ÃÅÐÌÀÍÈß) | AWD | | 205.24
|
| ÔÈÍËÅÏÑÈÍ ÒÀÁ. ÏÐÎËÎÍÃ.ÄÅÉÑÒÂ. 200ÌÃ ¹50 (AWD, ÃÅÐÌÀÍÈß) | AWD | | 162.65
|
| ÔÈÍËÅÏÑÈÍ ÒÀÁ. ÐÅÒÀÐÄ 400ÌÃ ¹50 (AWD, ÃÅÐÌÀÍÈß) | AWD | | 245.23
|
| ÔÈÒÎËÀÊÑ ÒÀÁ. 0,5Ã ¹20 (ÝÂÀËÀÐ, ÐÎÑÑÈß) | ÝÂÀËÀÐ | | 73.84
|
| ÔÈÒÎÑÛÂÎÐÎÒÊÀ ÂÎÇÐÎÆÄÅÍÈÅ È ÓÊÐÅÏ. ÎÑËÀÁ. ÂÎËÎÑ Ñ ÂÈÒ.Ä È ÊÎËËÀÃÅÍÎÌ 100ÌË ¹1 (ËÅÊÎÌÀÊÑ ÔÀÐÌÀ, ÐÎÑÑÈß) | ËÅÊÎÌÀÊÑ ÔÀÐÌÀ | | 140.8
|
| ÔËÀÌÈÍ ÃÐÀÍÓËÛ Ä/Ä 1,38Ã ¹20 (ÂÈÔÈÒÅÕ ÇÀÎ, ÐÎÑÑÈß) | ÂÈÔÈÒÅÕ ÇÀÎ | | 57.32
|
| ÔËÀÌÈÍ ÒÀÁ. 50ÌÃ ¹10 (ÂÈÔÈÒÅÕ ÇÀÎ, ÐÎÑÑÈß) | ÂÈÔÈÒÅÕ ÇÀÎ | | 32.32
|
| ÔËÀÌÈÍ ÒÀÁ. 50ÌÃ ¹30 (ÇÄÎÐÎÂÜÅ, ÓÊÐÀÈÍÀ) | ÇÄÎÐÎÂÜÅ | | 57.92
|
| ÔËÅÁÎÄÈÀ 600 ÒÀÁ. Ï/Î 600ÌÃ ¹30 (INNOTECH INTERNATIONAL, ÔÐÀÍÖÈß) | INNOTECH INTERNATIONAL | | 552.17
|
| ÔËÅÊÑÅÍ ÃÅËÜ 2,5% 30Ã ¹1 (ITALFARMACO, ÈÒÀËÈß) | ITALFARMACO | | 121.81
|
| ÔËÅÌÎÊËÀÂ ÑÎËÞÒÀÁ ÒÀÁ. 500ÌÃ+125ÌÃ ¹20 (ASTELLAS PHARMA EUROPE B.V./ÎÐÒÀÒ, ÐÎÑÑÈß) | ASTELLAS PHARMA EUROPE B.V./ÎÐÒÀÒ | | 468.64
|
| ÔËÅÌÎÊËÀÂ ÑÎËÞÒÀÁ ÒÀÁ. ÄÈÑÏ. 500ÌÃ+125ÌÃ ¹20 (ASTELLAS PHARMA EUROPE B.V./ÎÐÒÀÒ, ÍÈÄÅÐËÀÍÄÛ/ÐÎÑÑÈß) | ASTELLAS PHARMA EUROPE B.V./ÎÐÒÀÒ | | 486.52
|
| ÔËÅÌÎÊÑÈÍ ÑÎËÞÒÀÁ ÒÀÁ. ÄÈÑÏ. 1000ÌÃ ¹20 (ASTELLAS PHARMA EUROPE B.V./ÎÐÒÀÒ, ÍÈÄÅÐËÀÍÄÛ/ÐÎÑÑÈß) | ASTELLAS PHARMA EUROPE B.V./ÎÐÒÀÒ | | 337.94
|
| ÔËÅÌÎÊÑÈÍ ÑÎËÞÒÀÁ ÒÀÁ. ÄÈÑÏ. 1000ÌÃ ¹20 (YAMANOUCHI/ÎÐÒÀÒ, ÍÈÄÅÐËÀÍÄÛ/ÐÎÑÑÈß) | YAMANOUCHI/ÎÐÒÀÒ | | 354.56
|
| ÔËÅÌÎÊÑÈÍ ÑÎËÞÒÀÁ ÒÀÁ. ÄÈÑÏ. 125ÌÃ ¹20 (ASTELLAS PHARMA EUROPE B.V., ÍÈÄÅÐËÀÍÄÛ) | ASTELLAS PHARMA EUROPE B.V. | | 164.8
|
| ÔËÅÌÎÊÑÈÍ ÑÎËÞÒÀÁ ÒÀÁ. ÄÈÑÏ. 500ÌÃ ¹20 (ASTELLAS PHARMA EUROPE B.V./ÎÐÒÀÒ, ÐÎÑÑÈß) | ASTELLAS PHARMA EUROPE B.V./ÎÐÒÀÒ | | 249.33
|
| ÔËÈÊÑÎÍÀÇÅ ÑÏÐÅÉ ÍÀÇ. 50ÌÊÃ 120ÄÎÇ ¹1 (GLAXOSMITHKLINE PHARMACEUTICALS, ÏÎËÜØÀ) | GLAXOSMITHKLINE PHARMACEUTICALS | | 553.65
|
| ÔËÈÊÑÎÍÀÇÅ ÑÏÐÅÉ ÍÀÇ. 50ÌÊÃ/ÄÎÇÀ 120 ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ) | GLAXO SMITH KLINE | | 587.54
|
| ÔËÈÊÑÎÒÈÄ ÀÝÐÎÇÎËÜ 125ÌÊÃ/ÄÎÇÀ 60 ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ) | GLAXO SMITH KLINE | | 630.29
|
| ÔËÈÊÑÎÒÈÄ ÀÝÐÎÇÎËÜ 250ÌÊÃ/ÄÎÇÀ 60 ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ) | GLAXO SMITH KLINE | | 905.58
|
| ÔËÈÊÑÎÒÈÄ ÀÝÐÎÇÎËÜ 50ÌÊÃ/ÄÎÇÀ 120 ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ) | GLAXO SMITH KLINE | | 166.02
|
| ÔËÈÊÑÎÒÈÄ ÀÝÐÎÇÎËÜ 50ÌÊÃ/ÄÎÇÀ 120 ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ) | GLAXO SMITH KLINE | | 394.77
|
| ÔËÈÒ ÔÎÑÔÎ-ÑÎÄÀ Ð-Ð Ä/ÂÍÓÒÐ.ÏÐÈÌ. 45ÌË ¹2 (LABORATORIOS CASEN FLEET, ÃÅÐÌÀÍÈß) | LABORATORIOS CASEN FLEET | | 715.82
|
| ÔËÎÃÝÍÇÈÌ ÒÀÁ. Ï/Î ¹100 (MUCOS PHARMA, ÃÅÐÌÀÍÈß) | MUCOS PHARMA | | 1251.23
|
| ÔËÎÃÝÍÇÈÌ ÒÀÁ. Ï/Î ¹40 (MUCOS PHARMA, ÃÅÐÌÀÍÈß) | MUCOS PHARMA | | 544.09
|
| ÔËÎÊÑÀË ÊÀÏËÈ ÃËÀÇÍÛÅ 0,3% 5ÌË ¹1 (DR. GERHARD MANN CHEM. - PHARM.FABRIK, ÃÅÐÌÀÍÈß) | DR. GERHARD MANN CHEM. - PHARM.FABRIK | | 161.85
|
| ÔËÎÊÑÀË ÌÀÇÜ ÃËÀÇÍÀß 0,3% 3Ã ¹1 (BAUSCH & LOMB, ÃÅÐÌÀÍÈß) | BAUSCH & LOMB | | 178.44
|
| ÔËÎÐÀÖÈÄ ÒÀÁ. Ï/Î 250ÌÃ ¹5 (ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ, ÐÎÑÑÈß) | ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ | | 238.76
|
| ÔËÎÐÀÖÈÄ ÒÀÁ. Ï/Î 500ÌÃ ¹5 (ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ/ÎÁÎËÅÍÑÊÎÅ, ÐÎÑÑÈß) | ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ/ÎÁÎËÅÍÑÊÎÅ | | 432.91
|
| ÔËÎÐÈÍ ÔÎÐÒÅ ÏÎÐ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. ¹30 (ÏÀÐÒÍÅÐ, ÐÎÑÑÈß) | ÏÀÐÒÍÅÐ | | 481.8
|
| ÔËÓÈÌÓÖÈË ÀÍÒÈÁÈÎÒÈÊ ÈÒ ÏÎÐ. Ä/ÈÍ 500ÌÃ ¹3 +Ð-ËÜ (ZAMBON GROUP, ÈÒÀËÈß) | ZAMBON GROUP | | 366
|
| ÔËÓÈÌÓÖÈË ÃÐÀÍÓËÛ Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÂÍÓÒÐ.ÏÐÈÌ. 200ÌÃ 1Ã ¹20 (ZAMBON GROUP, ØÂÅÉÖÀÐÈß) | ZAMBON GROUP | | 148.55
|
| ÔËÓÈÌÓÖÈË Ð-Ð Ä/ÈÍ. 300ÌÃ 3ÌË ¹5 (ZAMBON GROUP, ÈÒÀËÈß) | ZAMBON GROUP | | 187.48
|
| ÔËÓÈÌÓÖÈË ÒÀÁ. ØÈÏÓ×ÈÅ 600Ìà ¹10 (ZAMBON GROUP, ØÂÅÉÖÀÐÈß) | ZAMBON GROUP | | 114.41
|
| ÔËÓÈÔÎÐÒ ÃÐÀÍÓËÛ Ä/ÏÐÈÃ.ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 5Ã ¹10 (DOMPE FARMACEUTICI S.P.A., ÈÒÀËÈß) | DOMPE FARMACEUTICI S.P.A. | | 279.79
|
| ÔËÓÊÎÍÀÇÎË ÊÀÏÑ. 150ÌÃ ¹1 (ÁÈÎÊÎÌ ÇÀÎ, ÐÎÑÑÈß) | ÁÈÎÊÎÌ ÇÀÎ | | 21.38
|
| ÔËÓÊÎÍÀÇÎË ÊÀÏÑ. 150ÌÃ ¹1 (ÎÁÎËÅÍÑÊÎÅ, ÐÎÑÑÈß) | ÎÁÎËÅÍÑÊÎÅ | | 20.97
|
| ÔËÓÊÎÍÀÇÎË ÊÀÏÑ. 150ÌÃ ¹1 (ÎÇÎÍ, ÐÎÑÑÈß) | ÎÇÎÍ | | 16.2
|
| ÔËÓÊÎÍÀÇÎË ÊÀÏÑ. 50ÌÃ ¹7 (ÁÈÎÊÎÌ ÇÀÎ, ÐÎÑÑÈß) | ÁÈÎÊÎÌ ÇÀÎ | | 40.79
|
| ÔËÓÊÎÍÀÇÎË ÊÀÏÑ. 50ÌÃ ¹7 (ÎÇÎÍ, ÐÎÑÑÈß) | ÎÇÎÍ | | 43.02
|
| ÔËÓÎÊÑÅÒÈÍ ÊÀÏÑ. 10ÌÃ ¹20 (ÁÈÎÊÎÌ ÇÀÎ, ÐÎÑÑÈß) | ÁÈÎÊÎÌ ÇÀÎ | | 46.34
|
| ÔËÓÎÊÑÅÒÈÍ ÊÀÏÑ. 20ÌÃ ¹20 (ÁÈÎÊÎÌ ÇÀÎ, ÐÎÑÑÈß) | ÁÈÎÊÎÌ ÇÀÎ | | 60.9
|
| ÔËÓÎÊÑÅÒÈÍ ÊÀÏÑ. 20ÌÃ ¹20 (ÎÇÎÍ, ÐÎÑÑÈß) | ÎÇÎÍ | | 42.84
|
| ÔËÓÎÊÑÅÒÈÍ ÊÀÏÑ. 20ÌÃ ¹30 (ÀËÑÈ ÔÀÐÌÀ ÇÀÎ, ÐÎÑÑÈß) | ÀËÑÈ ÔÀÐÌÀ ÇÀÎ | | 66.55
|
| ÔËÓÖÈÍÀÐ ÃÅËÜ 0,025% 15Ã ¹1 (JELFA, ÏÎËÜØÀ) | JELFA | | 94.16
|
| ÔËÓÖÈÍÀÐ ÌÀÇÜ 0,025% 15Ã ¹1 (JELFA, ÏÎËÜØÀ) | JELFA | | 109.78
|
| ÔËÓÖÈÍÀÐ Í ÌÀÇÜ 15Ã ¹1 (JELFA, ÏÎËÜØÀ) | JELFA | | 84.36
|
| ÔËÞÀÍÊÑÎË Ð-Ð Ä/ÈÍ.ÌÀÑË. 20ÌÃ/ÌË 1ÌË ¹10 (H LUNDBECK, ÄÀÍÈß) | H LUNDBECK | | 2035.7
|
| ÔËÞÀÍÊÑÎË ÒÀÁ. Ï/Î 0,5ÌÃ ¹50 (H LUNDBECK, ÄÀÍÈß) | H LUNDBECK | | 290.88
|
| ÔËÞÀÍÊÑÎË ÒÀÁ. Ï/Î 1ÌÃ ¹50 (H LUNDBECK, ÄÀÍÈß) | H LUNDBECK | | 429.68
|
| ÔËÞÀÍÊÑÎË ÒÀÁ. Ï/Î 5ÌÃ ¹100 (H LUNDBECK, ÄÀÍÈß) | H LUNDBECK | | 1081.34
|
| ÔËÞÄÈÒÅÊ ÑÈÐÎÏ 2% 125ÌË ¹1 (INNOTHERA CHOUZY, ÔÐÀÍÖÈß) | INNOTHERA CHOUZY | | 148.04
|
| ÔËÞÄÈÒÅÊ ÑÈÐÎÏ 5% 125ÌË ¹1 (INNOTHERA CHOUZY, ÔÐÀÍÖÈß) | INNOTHERA CHOUZY | | 145.04
|
| ÔËÞÊÎËÄÅÊÑ-Í ÒÀÁ. ¹12 (NABROS PHARMA, ÈÍÄÈß) | NABROS PHARMA | | 52.4
|
| ÔËÞÊÎÑÒÀÒ ÊÀÏÑ. 150ÌÃ ¹1 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ | | 143.31
|
| ÔËÞÊÎÑÒÀÒ ÊÀÏÑ. 50ÌÃ ¹7 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ | | 224
|
| ÔÎÇÈÊÀÐÄ ÒÀÁ. 10ÌÃ ¹28 (ACTAVIS, ÁÎËÃÀÐÈß) | ACTAVIS | | 137.99
|
| ÔÎÇÈÊÀÐÄ ÒÀÁ. 20ÌÃ ¹28 (ACTAVIS, ÁÎËÃÀÐÈß) | ACTAVIS | | 165.21
|
| ÔÎÇÈÊÀÐÄ ÒÀÁ. 20ÌÃ ¹28 (ACTAVIS, ÈÑËÀÍÄÈß) | ACTAVIS | | 147.46
|
| ÔÎÊÓÑÈÍ ÊÀÏÑ. 0,4ÌÃ ¹30 (ZENTIVA A.S., ÑËÎÂÀÊÈß) | ZENTIVA A.S. | | 521.42
|
| ÔÎËÀÖÈÍ ÒÀÁ. 5ÌÃ ¹30 (JADRAN, ÕÎÐÂÀÒÈß) | JADRAN | | 100.89
|
| ÔÎËÈÅÂÀß ÊÈÑËÎÒÀ ÒÀÁ. 1ÌÃ ¹50 (ÁÎÐÈÑÎÂÑÊÈÉ ÇÌÏ, ÁÅËÀÐÓÑÜ) | ÁÎÐÈÑÎÂÑÊÈÉ ÇÌÏ | | 18.26
|
| ÔÎËÈÅÂÀß ÊÈÑËÎÒÀ ÒÀÁ. 1ÌÃ ¹50 (ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ, ÐÎÑÑÈß) | ÂÀËÅÍÒÀ ÔÀÐÌÀÖÅÂÒÈÊÀ | | 19.3
|
| ÔÎËÈÅÂÀß ÊÈÑËÎÒÀ ÒÀÁ. 1ÌÃ ¹50 (ÎÇÎÍ, ÐÎÑÑÈß) | ÎÇÎÍ | | 18.73
|
| ÔÎÐÀÄÈË ÊÀÏÑ. 12ÌÊÃ ¹30 (NOVARTIS PHARMA, ØÂÅÉÖÀÐÈß) | NOVARTIS PHARMA | | 677.05
|
| ÔÎÐËÀÊÑ ÏÎÐ.Ä/Ä 4Ã ¹20 (BEAUFOUR IPSEN, ÔÐÀÍÖÈß) | BEAUFOUR IPSEN | | 226.97
|
| ÔÎÐËÀÊÑ ÏÎÐÎØÎÊ 10Ã ¹10 (BEAUFOUR IPSEN, ÔÐÀÍÖÈß) | BEAUFOUR IPSEN | | 129.72
|
| ÔÎÐËÀÊÑ ÏÎÐÎØÎÊ 10Ã ¹20 (BEAUFOUR IPSEN, ÔÐÀÍÖÈß) | BEAUFOUR IPSEN | | 240.15
|
| ÔÎÐÌÈÄÐÎÍ Ð-Ð Ä/ÍÀÐÓÆ.ÏÐÈÌ. 100ÌË (ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ | | 12.94
|
| ÔÎÐÌÈÄÐÎÍ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 50ÌË ¹1 (ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ | | 5.8
|
| ÔÎÐÌÓËÀ ÑÍÀ ÒÀÁ. 500ÌÃ ¹40 (ÝÂÀËÀÐ, ÐÎÑÑÈß) | ÝÂÀËÀÐ | | 73.04
|
| ÔÎÐÒÐÀÍÑ ÏÎÐÎØÎÊ 64Ã ¹4 (BEAUFOUR IPSEN, ÔÐÀÍÖÈß) | BEAUFOUR IPSEN | | 506.52
|
| ÔÎÐÒÓÌ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 1Ã ¹1 (GLAXO SMITH KLINE, ÈÒÀËÈß) | GLAXO SMITH KLINE | | 337.57
|
| ÔÎÐÒÓÌ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 2Ã ¹1 (GLAXO SMITH KLINE, ÈÒÀËÈß) | GLAXO SMITH KLINE | | 460.64
|
| ÔÎÑÔÀËÞÃÅËÜ ÃÅËÜ Ä/ÂÍÓÒÐ.ÏÐÈÌ. 16Ã ¹20 (YAMANOUCHI/PHARMATIS, ÔÐÀÍÖÈß) | YAMANOUCHI/PHARMATIS | | 189.27
|
| ÔÎÑÔÎÃËÈÂ ËÈÎÔ.Ä/ÏÐÈÃ.Ð-ÐÀ ÄËß Â/Â ÂÂÅÄ. 2,5Ã ¹5 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ | | 1224.19
|
| ÔÎÒÈË ÊÀÏËÈ ÃËÀÇÍÛÅ 5ÌË ¹1 (SANTEN, ÔÈÍËßÍÄÈß) | SANTEN | | 131.34
|
| ÔÎÒÈË ÔÎÐÒÅ ÊÀÏËÈ ÃËÀÇÍÛÅ 5ÌË ¹1 (SANTEN, ÔÈÍËßÍÄÈß) | SANTEN | | 134.61
|
| ÔÐÀÃÌÈÍ Ð-Ð Ä/ÈÍ. 2500 ÌÅ 0,2ÌË ¹10 (PFIZER/VETTER PHARMA-FERTIGUNG FOR PHARMACIA, ÃÅÐÌÀÍÈß) | PFIZER/VETTER PHARMA-FERTIGUNG FOR PHARMACIA | | 1965.03
|
| ÔÐÀÃÌÈÍ Ð-Ð Ä/ÈÍ. 5000 ÌÅ 0,2ÌË ¹10 (PFIZER/PHARMACIA&UPJOHN, ÃÅÐÌÀÍÈß) | PFIZER/PHARMACIA&UPJOHN | | 2594.23
|
| ÔÐÀÊÑÈÏÀÐÈÍ Ð-Ð Ä/ÈÍ. 9500ÌÅ (2850ÌÅ) 0,3ÌË ¹10 ØÏÐÈÖ (GLAXO WELLCOME, ÔÐÀÍÖÈß) | GLAXO WELLCOME | | 1522.35
|
| ÔÐÀÊÑÈÏÀÐÈÍ Ð-Ð Ä/ÈÍ. 9500ÌÅ (5700ÌÅ) 0,6ÌË ¹10 ØÏÐÈÖ (GLAXO WELLCOME, ÔÐÀÍÖÈß) | GLAXO WELLCOME | | 2752.66
|
| ÔÐÈÄÅÐÌ ÄÅÃÎÒÜ ØÀÌÏÓÍÜ 150ÌË ¹1 (SCHERING PLOUGH, ÃÅÐÌÀÍÈß) | SCHERING PLOUGH | | 385.96
|
| ÔÐÎÌÈËÈÄ ÒÀÁ. 250ÌÃ ¹14 (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 134.63
|
| ÔÐÎÌÈËÈÄ ÒÀÁ. 500ÌÃ ¹14 (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 492.66
|
| ÔÐÓÊÒÎÇÀ ÍÎÂÀÑÂÈÒ 500 Ã (ÍÎÂÀ ÏÐÎÄÓÊÒ ÀÃ ÎÎÎ, ÐÎÑÑÈß) | ÍÎÂÀ ÏÐÎÄÓÊÒ ÀÃ ÎÎÎ | | 59.75
|
| ÔÒÀËÀÇÎË ÒÀÁ. 500ÌÃ ¹10 (ÈÐÁÈÒÑÊÈÉ ÕÔÇ, ÐÎÑÑÈß) | ÈÐÁÈÒÑÊÈÉ ÕÔÇ | | 8.92
|
| ÔÒÎÐÎÊÎÐÒ ÌÀÇÜ 0,1% 15Ã ¹1 (GEDEON RICHTER, ÂÅÍÃÐÈß) | GEDEON RICHTER | | 125.56
|
| ÔÓÇÈÄÈÍ-ÍÀÒÐÈß ÒÀÁ. 125ÌÃ ¹20 (ÁÈÎÑÈÍÒÅÇ, ÐÎÑÑÈß) | ÁÈÎÑÈÍÒÅÇ | | 350.86
|
| ÔÓÊÎÐÖÈÍ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.ÑÏÈÐÒ. 10ÌË ¹1 (ßÐÎÑËÀÂÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ßÐÎÑËÀÂÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ | | 7.74
|
| ÔÓÊÎÐÖÈÍ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.ÑÏÈÐÒ. 25ÌË ¹1 (ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ | | 9.71
|
| ÔÓÍÃÎÒÅÐÁÈÍ ÊÐÅÌ 1% 15Ã ¹1 (ÍÈÆÔÀÐÌ, ÐÎÑÑÈß) | ÍÈÆÔÀÐÌ | | 158.66
|
| ÔÓÍÃÎÒÅÐÁÈÍ ÒÀÁ. 250ÌÃ ¹10 (ÍÈÆÔÀÐÌ, ÐÎÑÑÈß) | ÍÈÆÔÀÐÌ | | 398.71
|
| ÔÓÐÀÃÈÍ ÒÀÁ. 50ÌÃ ¹10 (ÎÁÎËÅÍÑÊÎÅ, ÐÎÑÑÈß) | ÎÁÎËÅÍÑÊÎÅ | | 12.92
|
| ÔÓÐÀÃÈÍ ÒÀÁ. 50ÌÃ ¹30 (ÎÁÎËÅÍÑÊÎÅ, ÐÎÑÑÈß) | ÎÁÎËÅÍÑÊÎÅ | | 32.18
|
| ÔÓÐÀÃÈÍ ÒÀÁ. 50ÌÃ ¹30 (ÎËÀÉÍÔÀÐÌ, ËÀÒÂÈß) | ÎËÀÉÍÔÀÐÌ | | 67.84
|
| ÔÓÐÀÄÎÍÈÍ ÒÀÁ. 50ÌÃ ¹10 (ÁÎÐÈÑÎÂÑÊÈÉ ÇÌÏ, ÁÅËÀÐÓÑÜ) | ÁÎÐÈÑÎÂÑÊÈÉ ÇÌÏ | | 3.47
|
| ÔÓÐÀÄÎÍÈÍ ÒÀÁ. 50ÌÃ ¹10 (ÈÐÁÈÒÑÊÈÉ ÕÔÇ, ÐÎÑÑÈß) | ÈÐÁÈÒÑÊÈÉ ÕÔÇ | | 1.73
|
| ÔÓÐÀÇÎËÈÄÎÍ ÒÀÁ. 50ÌÃ ¹10 (ÁÎÐÈÑÎÂÑÊÈÉ ÇÌÏ, ÁÅËÀÐÓÑÜ) | ÁÎÐÈÑÎÂÑÊÈÉ ÇÌÏ | | 2.54
|
| ÔÓÐÀÇÎËÈÄÎÍ ÒÀÁ. 50ÌÃ ¹10 (ÈÐÁÈÒÑÊÈÉ ÕÔÇ, ÐÎÑÑÈß) | ÈÐÁÈÒÑÊÈÉ ÕÔÇ | | 1.62
|
| ÔÓÐÀÌÀÃ ÊÀÏÑ. 25ÌÃ ¹30 (ÎËÀÉÍÔÀÐÌ, ËÀÒÂÈß) | ÎËÀÉÍÔÀÐÌ | | 191.26
|
| ÔÓÐÀÌÀÃ ÊÀÏÑ. 50ÌÃ ¹30 (ÎËÀÉÍÔÀÐÌ, ËÀÒÂÈß) | ÎËÀÉÍÔÀÐÌ | | 272.74
|
| ÔÓÐÀÖÈËÈÍ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. ÑÏÈÐÒ. 1:1500 0,067% 10ÌË ¹1 (ßÐÎÑËÀÂÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ßÐÎÑËÀÂÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ | | 5.09
|
| ÔÓÐÀÖÈËÈÍ ÒÀÁ. 20ÌÃ ¹10 (ÄÀËÜÕÈÌÔÀÐÌ ÎÀÎ, ÐÎÑÑÈß) | ÄÀËÜÕÈÌÔÀÐÌ ÎÀÎ | | 1.7
|
| ÔÓÐÀÖÈËÈÍ ÒÀÁ. 20ÌÃ ¹10 (ÈÐÁÈÒÑÊÈÉ ÕÔÇ, ÐÎÑÑÈß) | ÈÐÁÈÒÑÊÈÉ ÕÔÇ | | 1.62
|
| ÔÓÐÀÖÈËÈÍ ÒÀÁ. 20ÌÃ ¹10 (ÒÀÒÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ, ÐÎÑÑÈß) | ÒÀÒÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ | | 1.63
|
| ÔÓÐÎÑÅÌÈÄ Ð-Ð Ä/ÈÍ. 1% 2ÌË ¹10 (ÄÀËÜÕÈÌÔÀÐÌ ÎÀÎ, ÐÎÑÑÈß) | ÄÀËÜÕÈÌÔÀÐÌ ÎÀÎ | | 11.09
|
| ÔÓÐÎÑÅÌÈÄ Ð-Ð Ä/ÈÍ. 1% 2ÌË ¹10 (ÌÎÑÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ, ÐÎÑÑÈß) | ÌÎÑÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ | | 10.89
|
| ÔÓÐÎÑÅÌÈÄ ÒÀÁ. 40ÌÃ ¹50 (SOPHARMA, ÁÎËÃÀÐÈß) | SOPHARMA | | 10.85
|
| ÔÓÐÎÑÅÌÈÄ ÒÀÁ. 40ÌÃ ¹50 (ÁÈÎÑÈÍÒÅÇ, ÐÎÑÑÈß) | ÁÈÎÑÈÍÒÅÇ | | 8.94
|
| ÔÓÐÎÑÅÌÈÄ ÒÀÁ. 40ÌÃ ¹50 (ÌÎÑÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ, ÐÎÑÑÈß) | ÌÎÑÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ | | 7.99
|
| ÔÓÐÎÑÅÌÈÄ ÒÀÁ. 40ÌÃ ¹50 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ÒÎÌÑÊÕÈÌÔÀÐÌ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ-ÒÎÌÑÊÕÈÌÔÀÐÌ | | 9.52
|
| ÔÓÖÈÄÈÍ Ã ÊÐÅÌ 15Ã ¹1 (LEO LABORATORIÓS LIMITED, ÈÐËÀÍÄÈß) | LEO LABORATORIÓS LIMITED | | 321.16
|
| ÔÓÖÈÄÈÍ ÊÐÅÌ 2% 15Ã ¹1 (LEO LABORATORIÓS LIMITED, ÈÐËÀÍÄÈß) | LEO LABORATORIÓS LIMITED | | 286.25
|
| ÔÓÖÈÄÈÍ ÌÀÇÜ 2% 15Ã ¹1 (LEO PHARMACEUTICAL PRODUCTS, ÄÀÍÈß) | LEO PHARMACEUTICAL PRODUCTS | | 286.25
|
| ÔÓÖÈÊÎÐÒ ÊÐÅÌ 15Ã ¹1 (LEO LABORATORIÓS LIMITED, ÈÐËÀÍÄÈß) | LEO LABORATORIÓS LIMITED | | 321.16
|
| ÔÓÖÈÒÀËÌÈÊ ÊÀÏËÈ ÃËÀÇÍÛÅ 1% 5Ã ¹1 (LEO PHARMACEUTICAL PRODUCTS, ÄÀÍÈß) | LEO PHARMACEUTICAL PRODUCTS | | 287.07
|
